Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine

Clinical Journal of Oncology Nursing

Volumn 15, Issue 1, 2011, Pages

  Dressel, Amanda ^a   Kwari, Monica ^b   McGreal, Ann M ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Oncology Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE; CLOFARABINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; MONITORING; NURSING;

ADENINE NUCLEOTIDES; ADULT; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLINICAL TRIALS AS TOPIC; HUMANS; MONITORING, PHYSIOLOGIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 79953073262     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/11.CJON.E13-E23     Document Type: Article

References (28)

1. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Petersdorf, S.H. (2006). Age and acute myeloid leukemia. Blood, 107, 3481-3485. doi: 10.1182/blood-2005-09-3724
2. Burnett, A.K., Baccarani, M., Johnson, P., Yin, J., Saunders, A., Russell, N., & Hills, R.K. (2006). A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia [Abstract 425]. Presented at the American Society of Hematology's 48th Annual Meeting and Exposition, December 9-12, in Orlando, FL.
3. Burnett, A.K., & Mohite, U. (2006). Treatment of older patients with acute myeloid leukemia-new agents. Seminars in Hematology, 43, 96-106. doi: 10.1053/j.seminhematol.2006.01.003
4. Burnett, A.K., Russell, N., Kell, J.W., Milligan, D., & Culligan, D. (2004). A phase 2 evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy [Abstract 869]. Blood, 104, 248a.
5. Clofarabine. (2004). Drugs in R&D, 5, 213-217.
6. Coiffier, B., Altman, A., Pui, C.H., Younes, A., & Cairo, M.S. (2008). Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. Journal of Clinical Oncology, 26, 2767-2778. doi: 10.1200/JCO.2007.15.0177
7. Eastern Cooperative Oncology Group. (2006). ECOG performance status. Retrieved from http://ecog.dfci.harvard.edu/general/perf_stat.html
8. Faderl, S., Gandhi, V., O'Brien, S., Bonate, P., Cortes, J., Estey, E.,. Kantarjian, H. (2005). Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 105, 940-947. doi: 10.1182/blood-2004-05-1933
9. Faderl, S., Ravandi, F., Huang, X., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Kantarjian, H.M. (2008). A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 112, 1638-1645. doi: 10.1182/blood-2007-11-124602
10. Faderl, S., Verstovsek, S., Cortes, J., Ravandi, F., Beran, M., Garcia-Manero, G., Kantarjian, H.M. (2006). Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood, 108, 45-51. doi: 10.1182/blood-2005-08-3294
11. Genzyme. (2008). Clolar™ [Product insert]. Cambridge, MA: Author.
12. Jeha, S., Gandhi, V., Chan, K.W., McDonald, L., Ramirez, I., Madden, R., Kantarjian, H. (2004). Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 103, 784-789. doi: 10.1182/blood-2003-06-2122
13. Jeha, S., Gaynon, P.S., Razzouk, B.I., Franklin, J., Kadota, R., Shen, V., Steinherz, P. (2006). Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Journal of Clinical Oncology, 24, 1917-1923. doi: 10.1200/JCO.2005.03.8554
14. Jemal, A., Siegel, R., Xu, J. & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277-300. doi: 10.3322/caac.20073
15. Kantarjian, H.M., Erba, H.P., Claxton, D., Arellano, M., Lyons, R.M., Faderl, S. (2010). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Journal of Clinical Oncology, 28, 521-523. doi: 10.1200/JCO.2009.23.3130
16. Kantarjian, H.M., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Freireich, E.J. (2003). Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 102, 2379-2386. doi: 10.1182/blood-2003-03-0925
17. Kantarjian, H.M., Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., Keating, M. (2003). Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Journal of Clinical Oncology, 21, 1167-1173. doi: 10.1200/JCO.2003.04.031
18. Klepin, H.D., & Balducci, L. (2009). Acute myelogenous leukemia in older adults. Oncologist, 14, 222-232. doi: 10.1634/theoncolog ist.2008-0224
19. Lancet, J.E., & Giralt, S. (2008). Therapy for older AML patients: The role of novel agents and allogeneic stem cell transplant. Journal of the National Comprehensive Cancer Network, 6, 1017-1025.
20. McGraw, B. (2008). At an increased risk: Tumor lysis syndrome. Clinical Journal of Oncology Nursing, 12, 563-565. doi: 10.1188 /08.CJON.563-565
21. Montgomery, J.A., Shortnacy-Fowler, A.T., Clayton, S.D., Riordan, J.M., & Secrist, J.A., 3rd. (1992). Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. Journal of Medical Chemistry, 35, 397-401. doi: 10.1021/jm00080a029
22. Nabhan, C., Davis, N., Bitran, J.D., Galvez, A., Fried, W., Tolzien, K., Venugopal, P. (2010). Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/cncr.25603/abstract
23. National Comprehensive Cancer Network. (2010). Clinical Practice Guidelines in Oncology™: Acute myeloid leukemia [v.2.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
24. Parker, W.B., Shaddix, S.C., Chang, C.H., White, E.L., Rose, L.M., Brockman, R.W., Bennett, L.L., Jr. (1991). Effects of 2-chloro-9 adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Research, 51, 2386-2394.
25. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Wolff, A.C. (2006). 2006 update of recommendations for the use of white blood cell growth factors. Journal of Clinical Oncology, 24, 3187-3205. doi: 10.1200/JCO.2006.06.4451
26. Vogler, W.R., Velez-Garcia, E., Weiner, R.S., Flaum, M.A., Bartolucci, A.A., Omura, G.A., Banks, P.L. (1992). A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. Journal of Clinical Oncology, 10, 1103-1111.
27. Waddell, J.A., & Solimando, D.A. (2002). Cytarabine and daunorubicin regimen for remission induction of acute myelogenous leukemia. Hospital Pharmacy, 37, 1044-1048.
28. Yates, J., Glidewell, O., Wiernik, P., Cooper, M.R., Steinberg, D., Dosik, H., Holland, J.F. (1982). Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood, 60, 454-462